Mankind Pharma Share Price
₹2,505.55 -58 (-2.26%)
22 Jan, 2025 12:26
Start SIP in MANKIND
Start SIPPerformance
- Low
- ₹2,503
- High
- ₹2,586
- 52 Week Low
- ₹1,901
- 52 Week High
- ₹3,055
- Open Price₹2,574
- Previous Close₹2,564
- Volume131,562
Investment Returns
- Over 1 Month -10.68%
- Over 3 Month -5.34%
- Over 6 Month + 17.69%
- Over 1 Year + 15.52%
Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!
Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 48.9
- PEG Ratio
- 1.4
- Market Cap Cr
- 103,371
- P/B Ratio
- 9.8
- Average True Range
- 108.46
- EPS
- 51.26
- Dividend Yield
- 0
- MACD Signal
- -5.09
- RSI
- 40.62
- MFI
- 39.75
Mankind Pharma Financials
Mankind Pharma Technicals
EMA & SMA
Current Price
₹2,505.55
-58
(-2.26%)
- Bearish Moving Average 13
- Bullish Moving Average 3
- 20 Day
- ₹2,716.35
- 50 Day
- ₹2,701.60
- 100 Day
- ₹2,612.50
- 200 Day
- ₹2,447.44
Resistance and Support
2601.35
- R3 2,787.20
- R2 2,737.85
- R1 2,650.70
- S1 2,514.20
- S2 2,464.85
- S3 2,377.70
Mankind Pharma Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-01-23 | Quarterly Results | |
2024-11-05 | Quarterly Results | |
2024-07-31 | Quarterly Results | |
2024-05-15 | Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
2024-01-31 | Quarterly Results |
Mankind Pharma F&O
About Mankind Pharma
- NSE Symbol
- MANKIND
- BSE Symbol
- 543904
- ISIN
- INE634S01028
Similar Stocks to Mankind Pharma
Mankind Pharma FAQs
Mankind Pharma share price is ₹2,505 As on 22 January, 2025 | 12:12
The Market Cap of Mankind Pharma is ₹103370.7 Cr As on 22 January, 2025 | 12:12
The P/E ratio of Mankind Pharma is 48.9 As on 22 January, 2025 | 12:12
The PB ratio of Mankind Pharma is 9.8 As on 22 January, 2025 | 12:12
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.